[1]贾东辉,杜 宇,黄 飞,等.食管癌患者行根治性切除术后血清miR-216a和Bcl-2mRNA表达水平及与预后的相关性研究[J].现代检验医学杂志,2022,37(02):93-99.[doi:10.3969/j.issn.1671-7414.2022.02.020]
 JIA Dong-hui,DU Yu,HUANG Fei,et al.Expression Levels of Serum miR-216a and Bcl-2 mRNA and Their Correlation with Prognosis in Patients with Esophageal Cancer after Radical Resection[J].Journal of Modern Laboratory Medicine,2022,37(02):93-99.[doi:10.3969/j.issn.1671-7414.2022.02.020]
点击复制

食管癌患者行根治性切除术后血清miR-216a和Bcl-2mRNA表达水平及与预后的相关性研究()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
93-99
栏目:
论 著
出版日期:
2022-03-15

文章信息/Info

Title:
Expression Levels of Serum miR-216a and Bcl-2 mRNA and Their Correlation with Prognosis in Patients with Esophageal Cancer after Radical Resection
文章编号:
1671-7414(2022)02-093-07
作者:
贾东辉杜 宇黄 飞郝艳坤
(保定市第二医院胸外科,河北保定 071000)
Author(s):
JIA Dong-hui DU Yu HUANG Fei HAO Yan-kun
(Department of Thoracic Surgery,the Second Hospital of Baoding, Hebei Baoding 071000, China)
关键词:
食管癌微小RNA-216aB淋巴细胞瘤-2信使核糖核酸
分类号:
R735.1;R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.020
文献标志码:
A
摘要:
目的 检测食管癌(esophageal cancer)患者行根治性切除术后血清中微小核糖核酸-216a(micro RNA-216a,miR-216a),B 淋巴细胞瘤-2(B-cell lymphoma-2, Bcl-2)信使核糖核酸(mRNA)表达水平,探讨二者与患者预后情况的关系。方法 选取2012 年10 月~ 2016 年5 月于保定市第二医院胸外科接受根治性切除术的食管癌患者152 例作为观察组,选取同期入院体检的健康人85 例作为对照组。根据5 年随访结果将观察组患者分为生存组49 例和死亡组103 例。采用实时荧光定量PCR 法检测观察组术前和术后、对照组体检时血清miR-216a 和Bcl-2 mRNA 表达水平;分析食管癌患者术后血清miR-216a 和Bcl-2 mRNA 表达水平与临床病理特征的关系;比较生存组与死亡组术后血清miR-216a 和Bcl-2 mRNA 表达水平;采用Kaplan-Meier 生存曲线分析食管癌患者术后血清miR-216a,Bcl-2 mRNA 表达水平与患者5 年总生存率的关系;COX 回归分析食管癌患者术后预后不良的危险因素;受试者工作特征(ROC)曲线分析术后血清miR-216a 和Bcl-2 mRNA 表达水平对食管癌患者术后预后不良的预测价值。结果 与对照组相比,观察组术前和术后血清miR-216a(2.05±0.42,1.36±0.30 vs 1.01±0.19)和Bcl-2 mRNA(1.54±0.33,0.99±0.21 vs 0.68±0.15)表达水平显著升高,差异均有统计学意义(F=304.585,353.080,均P =0.000),观察组术前血清miR-216a 和Bcl-2 mRNA 表达水平显著高于术后,差异有统计学意义(t=16.482,17.336,均P =0.000);食管癌患者术后血清miR-216a 和Bcl-2 mRNA 表达水平与患者TNM 分期、有无淋巴结转移有关,差异均有统计学意义(t=4.622 ~ 10.944,均P=0.000);死亡组术后血清miR-216a(1.50±0.34 )和 Bcl-2 mRNA(1.09±0.25)表达水平高于生存组(1.06±0.21,0.77±0.16),差异均有统计学意义(t=8.326,8.190,均P =0.000);miR-216a 低表达组患者5 年总生存率(50.63%)显著高于miR-216a 高表达组(12.33%),Bcl-2 mRNA 低表达组患者5 年总生存率(45.45%)显著高于Bcl-2 mRNA高表达组(18.67%),差异均有统计学意义(χ2=25.483,12.481,均P=0.000);COX 多因素回归分析结果显示,TNM 分期III ~ IV 期、有淋巴结转移、miR-216a 和Bcl-2 mRNA 高表达均为影响食管癌患者术后预后不良的独立危险因素(P=0.000 ~ 0.024);血清miR-216a,Bcl-2 mRNA 表达水平联合预测食管癌患者术后预后不良的曲线下面积0.936明显高于二者单独预测的0.864 和0.837(Z=2.077,2.723,P=0.038,0.006)。结论 食管癌患者血清miR-216a 和Bcl-2 mRNA 表达上调,且术后低于术前,表明与患者术后预后密切相关,二者联合检测对食管癌患者术后预后不良有一定的预测价值。
Abstract:
Objective To detect the expression levels of microRNA-216a (miR-216a) and B-cell lymphoma-2 (Bcl-2) messenger RNA (mRNA) in the serum of patients with esophageal cancer after radical operation, and explore the relationship between them and the prognosis of patients. Methods From October 2012 to May 2016, 152 esophageal cancer patients who underwent radical resection in department of thoracic surgery, Baoding Second Hospital were selected as the observation group, and 85 healthy people who were admitted to the hospital for physical examination at the same time were selected as the control group. According to the results of 5-year follow-up, the patients in the observation group were divided into survival group (49 cases) and death group (103 cases). The expression levels of serum miR-216a and Bcl-2 mRNA in the observation group preoperative and postoperative and the control group during physical examination were detected by real-time fluorescence quantitative PCR. Analyzed the relationship between the expression levels of serum miR-216a and Bcl-2 mRNA after operation and clinicopathological features in patients with esophageal cancer,and the expression levels of serum miR-216a and Bcl-2 mRNA after operation in survival group and death group were compared.Kaplan-Meier survival curve was used to analyze the relationship between the expression levels of serum miR-216a and Bcl-2 mRNA after operation and the 5-year overall survival rate of patients with esophageal cancer,and Cox regression analysis of risk factors for poor prognosis in patients with esophageal cancer after operation; receiver operating characteristic (ROC) curve analysis of postoperative serum miR-216a and Bcl-2 mRNA expression levels in predicting poor prognosis of patients with esophageal cancer. Results Compared with the control group, the expression levels of serum miR-216a (2.05±0.42, 1.36±0.30 vs 1.01±0.19) and Bcl-2 mRNA (1.54±0.33,0.99±0.21 vs 0.68±0.15) in the observation group were significantly higher before and after operation, the differences were statistically significant(F =304.585, 353.080, all P=0.000), and the expression levels of serum miR-216a (2.05±0.42 vs 1.36±0.30) and Bcl- 2 mRNA (1.54±0.33 vs 0.99±0.21) in the observation group before operation were significantly higher than those after operation,the differences were statistically significant (t=16.482, 17.336, all P=0.000)....

参考文献/References:

[1] 乔晓伟, 朱高培, 王喆, 等.基于年龄- 时期- 队列模型的中国男性人群食管癌发病与死亡趋势分析 [J]. 郑州大学学报(医学版), 2021, 56(2):164-169. QIAO Xiaowei, ZHU Gaopei, WANG Zhe, et al. Analysis of the incidence and mortality trend of esophageal cancer in Chinese male population based on age-period-cohort model [J]. Journal of Zhengzhou University(Medical Sciences), 2021, 56(2):164-169.
[2] 梁晓虎, 雷尚昆, 郭俊霞.食管癌组织中lnc RNA DNAJC3-AS1 的表达及其与临床病理特征的相关性 研究[J]. 现代检验医学杂志, 2021, 36(2):75-78. LIANG Xiaohu, LEI Shangkun, GUO Junxia. Expression of lnc RNA DNAJC3-AS1 in esophageal carcinoma tissues and its correlation with clinicopathological features [J]. Journal of Modern Laboratory Medicine, 2021, 36(2):75-78.
[3] WATANABE M, OTAKE R, KOZUKI R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surgery Today, 2020, 50(1): 12- 20.
[4] 倪文婕, 肖泽芬.食管癌术后辅助治疗的研究进展 [J]. 中华放射肿瘤学杂志, 2019, 28(12):945-948. NI Wenjie, XIAO Zefen. Research progress on postoperative adjuvant therapy for esophageal carcinoma [J]. Chinese Journal of Radiation Oncology, 2019, 28(12):945-948.
[5] 赵银龙, 王洪冰, 毛铁铸, 等.microRNA 与肿瘤 关系的研究进展[J]. 癌症进展, 2019, 17(12):1365- 1367, 1384. ZHAO Yinlong, WANG Hongbing, MAO Tiezhu, et al. Research progress on the relationship between microRNA and tumor[J]. Oncology Progress, 2019, 17(12):1365-1367, 1384.
[6] 苟兰琼, 何平, 郑连喜, 等.胃癌中miR-216 a 表达 的变化及其对胃癌细胞侵袭的靶向调控作用[J]. 川 北医学院学报, 2019, 34(4):347-350. GOU Lanqiong, HE Ping, ZHENG Lianxi, et al. Changes of miR-216 a expression in gastric cancer and its targeting regula-tion effect on invasion of gastric cancer cells [J]. Journal of North Sichuan Medical College, 2019, 34(4):347-350.
[7] ZHAO Rui, ZHANG Xin, ZHANG Yanli, et al. HOTTIP predicts poor survival in gastric cancer patients and contributes to cisplatin resistance by sponging miR-216a-5p[J]. Frontiers in Cell and Developmental Biology, 2020, 8: 348.
[8] 于洁, 卢博奇, 朱丽业, 等.长链非编码RNA H19 靶向Bcl-2 的表达调控宫颈癌细胞侵袭转移行为的 机制[J].解放军医药杂志, 2019, 31(1):12-17. YU Jie, LU Boqi, ZHU Liye, et al. Mechanism of longchain non-coding RNA H19 targeting Bcl-2 expression for regulating invasion and metastasis of cervical cancer cells [J]. Medical & Pharmaceutical Journal of Chinese People’s Liberation Army, 2019, 31(1):12-17.
[9] 尹博, 王兵, 牛磊, 等.VEGF 和Bcl-2 在食管癌患 者血清中的表达水平及其临床意义[J]. 癌症进展, 2019, 17(2):154-157. YIN Bo, WANG Bing, NIU Lei, et al. Expression of VEGF and Bcl-2 in serum of esophageal cancer and its clinical significance [J]. Oncology Progress, 2019, 17(2):154-157.
[10] TALSMA K, VAN HAGEN P, GROTENHUIS B A, et al. Comparison of the 6th and 7th editions of the UICCAJCC TNM classification for esophageal cancer[J]. Annals of Surgical Oncology, 2012, 19(7): 2142-2148.
[11] 中国抗癌协会食管癌专业协会委员会.食管癌规范 化诊治指南[M]. 2 版. 北京: 中国协和医科大学出 版社, 2013: 3-4. Esophageal Cancer Committee of Professional Association of China Anti Cancer Association. Clinical practice guidelines for the diagnosis and treatment of esophageal cancer [M]. 2nd Ed. Beijing: China Union Medical College Press, 2013:3-4.
[12] 国家消化内镜专业质控中心, 国家消化系疾病临床 医学研究中心, 国家消化道早癌防治中心联盟等. 中 国早期食管癌及癌前病变筛查专家共识意见(2019 年, 新乡)[J]. 中华消化内镜杂志, 2019, 36(11):793- 801. National Quality Control Center for Digestive Endoscopy, National Clinical Research Center for Digestive Diseases(Shanghai), National Early Gastrointestinal Cancer Prevention and Treatment Centers Alliance, et al. China experts consensus on the protocal of early esophageal cancer and pre-cancerous lesion screening (2019, Xinxiang) [J]. Chinese Journal of Health Management, 2019, 36(11):793-801.
[13] UHLENHOPP D J, THEN E O, SUNKARA T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors[J]. Clinical Journal of Gastroenterology, 2020, 13(6): 1010-1021.
[14] WANG Weidong, CHEN Yongqiang, ZHANG Xuewen, et al. A model shows utility in predicting postoperative recurrence and distant metastasis in curatively resected esophageal squamous cell cancer[J]. Cancer Control, 2019, 26(1):1073274819852965.
[15] CUI Ying, WANG Jinghao, LIU Shanshan, et al. miR 216a promotes breast cancer cell apoptosis by targeting PKCα[J]. Fundamental & Clinical Pharmacology, 2019, 33(4): 397-404.
[16] CUI Kaiying, ZHU Genhai. LncRNA CTBP1-AS2 regulates miR-216a/ PTEN to suppress ovarian cancer cell proliferation[J]. Journal of Ovarian Research, 2020, 13(1): 84.
[17] WANG Shensen, LIU Xinhui, KHAN A A, et al. MiR- 216a-mediated upregulation of TSPAN1 contributes to pancreatic cancer progression via transcriptional regulation of ITGA2[J]. American Journal of Cancer Research, 2020, 10(4): 1115-1129.
[18] 周维, 谭晓宇, 李慧芬, 等.MiR-216a-5p 通过 JAK2 靶向抑制肝癌细胞的增殖和侵袭[J]. 中国医药 生物技术, 2019, 14(2):155-163. ZHOU Wei, TAN Xiaoyu, LI Huifen, et al. MiR-216a-5p suppresses the proliferation and invasion of hepatocellular carcinoma cells through targeting JAK2 [J]. Chinese Medicinal Biotechnology, 2019, 14(2):155-163.
[19] 张同, 李庆, 舒若, 等.MiR-216a 在胃癌组织和患者 血浆中的表达变化及临床意义[J]. 重庆医学, 2019, 48 (7): 1155-1158. ZHANG Tong, LI Qing, SHU Ruo, et al. Different expression and clinical significance of miR-216a in tissue and plasma of gastric cancer patients [J]. Chongqing Medicine, 2019, 48(7):1155-1158.
[20] SAFARALIZADEH R, AJAMI N, NEMATI M, et al. Disregulation of miR-216a and miR-217 in gastric cancer and their clinical significance[J]. Journal of Gastrointestinal Cancer, 2019, 50(1): 78-83.
[21] TIMUCIN A C, BASAGA H, KUTUK O. Selective targeting of antiapoptotic BCL-2 proteins in cancer[J]. Medicinal Research Reviews, 2019, 39(1): 146-175.
[22] 袁丽, 张立玮, 尔丽绵, 等.Bcl-2 基因多态性与食管 和贲门癌的关联研究[J]. 中华预防医学杂志, 2019, 53(11): 1119-1123. YUAN Li, ZHANG Liwei, ER Limian, et al. The association of Bcl-2 gene polymorphism with the esophageal cancer and gastric cardia adenocarcinoma in Hebei Province [J]. Chinese Journal of Preventive Medicine, 2019, 53(11):1119-1123.
[23] D’AGUANNO S, DEL BUFALO D. Inhibition of antiapoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer [J]. Cells (Basel, Switzerland), 2020, 9(5): 1287.
[24] ELNAGGAR G N, EL-HIFNAWI N M, ISMAIL A, et al. Micro RNA-148a targets Bcl-2 in patients with Non-Small cell lung cancer[J]. Asian Pacific Journal of Cancer Prevention, 2021, 22(6): 1949-1955.
[25] 雷艳杰, 卜晓红.FHIT 蛋白、Bcl-2 蛋白、p53 蛋 白在胃癌中的表达及其与幽门螺旋杆菌感染的相关 性[J]. 实用癌症杂志, 2020, 35(6): 903-906. LEI Yanjie, BU Xiaohong. Expression levels of FHIT protein, Bcl-2 protein and p53 protein in patients with gastric cancer and their correlation with helicobacter pylori infection [J]. The Practical Journal of Cancer , 2020, 35(6):903-906.

相似文献/References:

[1]张 振,李 力,徐翠香,等.血清TAM和Cyfra21-1检测在食管癌诊断和化疗疗效判定中的价值[J].现代检验医学杂志,2015,30(04):150.[doi:10.3969/j.issn.1671-7414.2015.04.046]
 ZHANG Zhen,LI Li,X(¨overU)Cui-xiang,et al.Value of Detecting Serum TAM and Cyfra21-1 Levels in the Diagnosis and Chemotherapeutic Efficacy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2015,30(02):150.[doi:10.3969/j.issn.1671-7414.2015.04.046]
[2]朱卫华,刘继斌.血浆相关基因甲基化在食管癌复发中的临床价值[J].现代检验医学杂志,2016,31(04):93.[doi:10.3969/j.issn.16717-414.2016.04.025]
 ZHU Wei-hua,LIU Ji-bin.Clinical Significance of Promoter Hypermethylation of Esophageal Squamous Cell Carcinoma(ESCC)in Plasma[J].Journal of Modern Laboratory Medicine,2016,31(02):93.[doi:10.3969/j.issn.16717-414.2016.04.025]
[3]肖小平,张 熊sub>a,秦光明b.食管癌和良性食管疾病患者血浆miRNA-21和miRNA-143检测的临床应用研究[J].现代检验医学杂志,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
 XIAO Xiao-ping,ZHANG Xionga,QIN Guang-mingb.Clinical Research of Detecting Plasma MiRNA-21 and MiRNA-143 for Identifying Early Esophageal Cancer and Benign Esophageal Diseases[J].Journal of Modern Laboratory Medicine,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.04.020]
[4]邱 巍,胡 威,赵建江,等.江苏宿迁地区汉族人群DNMT3B基因启动子区-149C>T和-579G>T多态性与食管癌易感性的分析[J].现代检验医学杂志,2018,33(02):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
 QIU Wei,HU Wei,ZHAO Jian-jiang,et al.Study on the Promoter Region -149C>T and -579G>T Polymorphism of DNMT3B with Genetic Susceptibility to Esophageal Cancer of Han Population in Jiangsu Suqian[J].Journal of Modern Laboratory Medicine,2018,33(02):28.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[5]陈 津,彭 伟,崔兆磊,等.食管癌放疗患者血清涎液化糖链抗原水平检测在预测放射性肺炎的风险评估[J].现代检验医学杂志,2020,35(03):126.[doi:10.3969/j.issn.1671-7414.2020.03.034]
 CHEN Jin,PENG Wei,CUI Zhao-lei,et al.Serum KL-6 Predicts the Risk of Pneumonitis Induction after Radiotherapy of Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(02):126.[doi:10.3969/j.issn.1671-7414.2020.03.034]
[6]梁晓虎,郭俊霞,雷尚昆.食管癌组织中lnc RNA DNAJC3-AS1的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2021,36(02):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
 LIANG Xiao-hu,GUO Jun-xia,LEI Shangkun.Expression of Lnc RNA DNAJC3-AS1 in Esophageal Carcinoma Tissues and Its Correlation with Clinicopathological Features[J].Journal of Modern Laboratory Medicine,2021,36(02):75.[doi:doi:10.3969/j.issn.1671-7414.2021.02.018]
[7]朱 娇a,孙国才b,刘素荣a,等.食管癌患者血清神经元特异性烯醇化酶与长链非编码RNA ITGA9-AS1水平联合检测的实验诊断价值研究[J].现代检验医学杂志,2021,36(05):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
 ZHU Jiaoa,SUN Guo-caib,LIU Su-ronga,et al.Experimental Diagnostic Value of Combined Detection of SerumNeuron-Specific Enolase and Long Non-Coding RNA ITGA9-AS1 inPatients with Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(02):62.[doi:10.3969/j.issn.1671-7414.2021.05.014]
[8]刘 伟a,周 杨a,边 超a,等.miR-495 对食管癌细胞株Eca109 在不同放射剂量和顺铂浓度作用的影响及机制研究[J].现代检验医学杂志,2022,37(04):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]
 LIU Weia,ZHOU Yanga,BIAN Chaoa,et al.Effect of miR-495 on Esophageal Cancer Cell Line Eca109 at Different Radiation Doses and Cisplatin Concentrations and Its Mechanism[J].Journal of Modern Laboratory Medicine,2022,37(02):13.[doi:10.3969/j.issn.1671-7414.2022.04.003]
[9]周立远,叶玉祥,林 琳,等.LncRNA CCAT1 调节miR-155 表达增强CD8+T 细胞对食管癌抗肿瘤活性的机制研究[J].现代检验医学杂志,2023,38(03):79.[doi:10.3969/j.issn.1671-7414.2023.03.014]
 ZHOU Li-yuan,YE Yu-xiang,LIN Lin,et al.Mechanism of LncRNA CCAT1 Regulating miR-155 Expression and Enhancing Anti-tumor Activity of CD8+T Cells Against Esophageal Cancer[J].Journal of Modern Laboratory Medicine,2023,38(02):79.[doi:10.3969/j.issn.1671-7414.2023.03.014]

备注/Memo

备注/Memo:
基金项目:河北省医学科学研究重点课题计划项目(20181482)。
作者简介:贾东辉(1982-),男,本科,主治医师,研究方向:食管癌的诊治,E-mail:jiadh19@163.com。
更新日期/Last Update: 1900-01-01